Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors

Sorafenib is a RAF inhibitor approved for several cancers, including hepatocellular carcinoma (HCC). Inhibition of RAF kinases can induce a dose-dependent “paradoxical” upregulation of the downstream mitogen-activated protein kinase (MAPK) pathway in cancer cells. It is unknown whether “paradoxical”...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Sci Rep
Autori principali: Chen, Yunching, Liu, Ya-Chi, Sung, Yun-Chieh, Ramjiawan, Rakesh R., Lin, Ts-Ting, Chang, Chih-Chun, Jeng, Kuo-Shyang, Chang, Chiung-Fang, Liu, Chun-Hung, Gao, Dong-Yu, Hsu, Fu-Fei, Duyverman, Annique M., Kitahara, Shuji, Huang, Peigen, Dima, Simona, Popescu, Irinel, Flaherty, Keith T., Zhu, Andrew X., Bardeesy, Nabeel, Jain, Rakesh K., Benes, Cyril H., Duda, Dan G.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Publishing Group 2017
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5343435/
https://ncbi.nlm.nih.gov/pubmed/28276530
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/srep44123
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi